Seçki · Sağlık

Biotech

InspectStocks tarafındanPublished 14 Eki 202619 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

Bir yapay zekâ modelinin yardımıyla gruplandı ve editörlerimizce gözden geçirildi. Her şirketin altındaki satır, neden burada olduğunu söyler.

Download image

Kartlar Seviyeler

Hisse fiyatları 11 Kas 2026 kapanış fiyatlarıdır, IEX borsa verisinden.

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+%29,0

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap $138,7BP/E 35,22
$547,02+%26,01Y
Since added +%12,7
B+
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$13B+%10,5
Profit
$4B+%8,2
Free cash flow
$3,2B-%4,0
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap $101,3BP/E 21,18
$959,45+%41,51Y
Since added +%27,4
C+
Büyüme ve nakit
Büyüyor
Business trend
Hızlanıyor
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$16,9B+%18,6
Profit
$4,8B+%5,2
Free cash flow
$3,8B-%9,4
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap $210,5BF/K yok (faaliyet zararı)
$169,73+%40,91Y
Since added +%14,8
A
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Karışık
Getting better
İyileşiyor
Revenue
$31B+%6,5
Profit
-$3,9B-%147,6
Free cash flow
$13,8B+%50,4
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap $21,4BP/E 68,58
$159,80-%64,71Y
Since added -%28,6
B+
Büyüme ve nakit
Güçlü büyüyor
Business trend
Yavaşlıyor
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$3,7B+%65,2
Profit
$2,6B+%2.136,9
Free cash flow
$465,4M+%1.192,7
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap $37,5BP/E 109,22
$253,39+%56,91Y
Since added +%10,7
A
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Sağlam
Getting better
Karışık
Revenue
$10,3B+%2,3
Profit
$347,5M-%78,4
Free cash flow
$2,1B-%10,1
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap $26,5BF/K yok (faaliyet zararı)
$120,64-%37,91Y
Since added +%24,7
C-
Büyüme ve nakit
Büyüyor
Business trend
İstikrarlı
Business quality
Zayıf
Getting better
Karışık
Revenue
$1,5B+%240,0
Profit
-$605,6M+%48,8
Free cash flow
-$627,6M+%30,7
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap $25,4BP/E 22,48
$595,58+%29,01Y
Since added +%9,6
C+
Büyüme ve nakit
Güçlü büyüyor
Business trend
Yavaşlıyor
Business quality
Güçlü
Getting better
Belirgin biçimde iyileşiyor
Revenue
$3,2B+%1,9
Profit
$1,2B-%3,2
Free cash flow
$867,2M-%22,7
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap $17,6BP/E 25,87
$174,35+%18,71Y
Since added +%29,0
A+
Büyüme ve nakit
Güçlü büyüyor
Business trend
Hızlanıyor
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$3,7B+%38,0
Profit
$702,5M+%64,1
Free cash flow
$1B+%75,3
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap $100,6BF/K yok (faaliyet zararı)
$248,70+%831,11Y
Since added +%15,0
C-
Büyüme ve nakit
Büyüyor
Business trend
Hızlanıyor
Business quality
Zayıf
Getting better
Kötüleşiyor
Revenue
$2,5B+%13,1
Profit
-$2,8B+%10,5
Free cash flow
-$2B+%25,7
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap $11,3BNo P/E
$58,32+%5,41Y
Since added +%7,3
B
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Karışık
Getting better
İyileşiyor
Revenue
$3,7B+%18,1
Profit
-$19,1M-%103,7
Free cash flow
$557,9M-%33,0
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap $24,9BP/E 65,01
$122,23+%12,91Y
Since added +%12,6
C
Kâr ve defter değeri
Büyüyor
Business quality
Karışık
Getting better
Belirgin biçimde iyileşiyor
Revenue
$6B+%24,9
Profit
$403,4M-%66,1
Free cash flow
$892,1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap $17,3BP/E 21,17
$70,71+%62,21Y
Since added +%18,8
A+
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$2,5B+%9,1
Profit
$885,1M+%30,6
Free cash flow
$1,2B+%48,9
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap $22BF/K yok (faaliyet zararı)
$87,64-%21,51Y
Since added -%1,5
F
Büyüme ve nakit
Karışık
Business trend
Daralıyor
Business quality
Karışık
Getting better
İyileşiyor
Revenue
$2,7B-%23,2
Profit
-$1,6B-%157,7
Free cash flow
$314M+%456,5
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap $15,9BP/E 80,84
$248,18+%81,51Y
Since added +%18,0
A
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Karışık
Getting better
İyileşiyor
Revenue
$4,7B+%13,5
Profit
$206M+%155,9
Free cash flow
$1,6B+%21,3
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap $11,6BP/E 25,36
$101,69+%44,01Y
Since added -%7,2
A+
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$1,8B+%45,0
Profit
$485,4M-%18,5
Free cash flow
$885,9M+%47,1
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap $16,1BF/K yok (faaliyet zararı)
$259,10+%30,11Y
Since added +%16,0
D
Kâr ve defter değeri
Karışık
Business quality
Karışık
Getting better
İyileşiyor
Revenue
$1,2B+%113,4
Profit
-$254,8M+%39,7
Free cash flow
-$293,2M+%54,2
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap $15,5BF/K yok (faaliyet zararı)
$79,53+%20,11Y
Since added +%25,6
B
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Karışık
Getting better
Kötüleşiyor
Revenue
$945,5M+%167,3
Profit
-$573,8M+%28,6
Free cash flow
-$369,8M+%36,9
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap $8,2BP/E 58,68
$74,52-%4,91Y
Since added -%36,7
A+
Büyüme ve nakit
Güçlü büyüyor
Business trend
Hızlanıyor
Business quality
Güçlü
Getting better
Karışık
Revenue
$963,6M+%30,0
Profit
$162,3M+%52,9
Free cash flow
$194,6M+%19,2
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap $9,2BP/E 41,90
$308,82+%52,11Y
Since added -%3,9
A+
Büyüme ve nakit
Güçlü büyüyor
Business trend
İstikrarlı
Business quality
Güçlü
Getting better
İyileşiyor
Revenue
$470M+%26,0
Profit
$225,2M+%13,2
Free cash flow
$310,1M+%87,3
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.